Dexamethasone Infusion in Community-acquired Pneumonia

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether dexamethasone reduces the length of hospital stay in patient with a community-acquired pneumonia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St. Antonius Hospital
• Treatments: BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate

Criteria

Inclusion Criteria:

Patients aged 18 to 100 years with a community-acquired pneumonia.

Criteria to determine a community-acquired pneumonia:

• Chest radiograph showing new opacities

• In combination with two of the following findings:

• Cough

• Production of sputum

• Temp >38,0 °C or <36,0 °C

• Audible abnormalities by chest examination compatible with pneumonia

• Leukocytosis (>10.000 cells/mm3), leftward shift (>10%) or leukopenia (<4000 cells/mm3)

• CRP > 15 mg/dl (three times upper limit of normal)

Exclusion Criteria:

• o The following groups are excluded:

• Immunocompromised patients:

• Patients with a known congenital or achieved immunodeficiency.

• Patients who received chemotherapy less than 6 weeks ago.

• Patients who received corticosteroids in the last 6 weeks.

• Patients who received immunosuppressive medication in the last 6 weeks. (like cyclosporine, cyclofosfamide, azathioprine)

• Patients with COPD who are on systemic corticosteroids for COPD.

• Patients who require ICU treatment.